Drug Efficacy and Side-Effect Prediction Without 3D Structures
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional drug discovery methods rely heavily on human expertise and experimental validation, leading to low success rates and high costs, and AI-based methods struggle with predicting drug efficacy and side effects for proteins without known three-dimensional structures or requiring extensive experimentation.
Innovation Solution
A prediction device and method that integrates chemical, cellular, and clinical information using machine learning to estimate drug efficacy and side effects, incorporating neural networks and autoencoders to predict pharmacodynamics and pharmacokinetics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drug discovery methods relying on human expertise and experimental validation are used, then drug development can be performed with existing knowledge, but the success rate is low and costs are high
Solution Approach 1:
The patent replaces the mechanical system of human expertise and manual experimental validation with an AI-based prediction system. The machine learning model automatically analyzes chemical substance information and pharmacological data to predict drug efficacy and side effects, substituting human cognitive processes and manual experimentation with computational algorithms that can process data more efficiently and at lower cost.
Solution Approach 2:
The patent creates a virtual copy of the drug discovery process through machine learning models that simulate and predict drug behavior. Instead of physically synthesizing and testing every drug candidate, the system uses trained models to generate predictions about efficacy and side effects, allowing virtual screening of numerous candidates before committing to expensive wet-lab experiments.
2Productivity
If AI-based molecular docking methods are used to predict binding affinity, then prediction can be performed without extensive experimentation, but the method cannot be applied to proteins whose three-dimensional structures have not been accurately identified
Solution Approach 1:
The patent changes the input parameters from requiring three-dimensional structural data to accepting two-dimensional chemical substance information and pharmacological data. The machine learning model is trained to predict outcomes based on these alternative parameters, making the system applicable to a broader range of targets including membrane proteins and drug transporters whose structures are difficult to determine.
Solution Approach 2:
The patent creates a universal prediction system that can handle multiple types of drug targets and data formats. The machine learning model is designed to process diverse chemical substance information and pharmacological data to predict both binding affinity and biological activity, making it applicable to various protein types including those with unknown structures, thereby achieving multi-functionality.
3Measurement precision
If AI-based methods focusing on bioactivity are used, then direct prediction of quantitative structure-activity relationships can be achieved, but the methods are limited to drugs structurally similar to existing drugs and require astronomical experimentation
Solution Approach 1:
The patent performs preliminary action by pre-training machine learning models on extensive pharmacological data before actual drug discovery applications. The models are trained in advance on large datasets containing chemical substance information and corresponding pharmacological outcomes, so that when new drugs are evaluated, the predictions can be made quickly without requiring extensive new experimentation for each candidate.
Solution Approach 2:
The patent introduces machine learning models as intermediaries between chemical structure and pharmacological activity. Instead of directly correlating structure with activity through extensive experimentation, the trained models serve as mediators that have learned the relationships from training data, enabling accurate predictions with minimal new experimentation required.
4Productivity
If methods using only chemical structure information are used, then prediction can be performed without extensive experimentation, but only a partial view on the link between compound information and mechanisms of action is obtained
Solution Approach 1:
The patent merges multiple types of information including chemical substance information, pharmacological data, and cellular level biological information into a comprehensive prediction framework. The machine learning model integrates these diverse data sources to provide a more complete understanding of drug mechanisms of action while maintaining prediction efficiency, avoiding the need to choose between speed and completeness.
Data Source
AI summary
A prediction device includes: an acquisition unit that acquires chemical substance information of a drug and pharmacological information of the drug; an estimation unit that estimates estimated information of the drug by performing machine learning using the chemical substance information and the pharmacological information; and an output unit that predicts and outputs both efficacy and side effects of the drug on an organism by retraining a model of the machine learning on the basis of the estimated information.